Business Context and Reporting Period
Company: Smith & Nephew plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 05, 2026
Business Overview: A global medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It employs approximately 17,000 people and operates in over 100 countries.
Key Financial Metrics
This filing is a corporate governance disclosure and does not contain specific financial results for the reporting period.
- Revenue: The filing notes annual sales of $6.2 billion for the year 2025. No revenue data is provided for the period ending March 5, 2026.
- Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The primary material change disclosed in this filing is a corporate governance appointment:
- Executive Appointment: Deepak Nath, Chief Executive Officer of Smith & Nephew, has been appointed as an independent Non-Executive Director to the Board of Reckitt Benckiser Group plc.
- Effective Date: April 1, 2026.
- Regulatory Basis: Disclosure made in accordance with UK Listing Rule 6.4.9R(2).
Guidance, Outlook, and Risks
Outlook and Guidance: The filing contains no specific financial guidance or updated outlook for the current period. It includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ due to various risks.
Risks and Contingencies: The document lists numerous risk factors that could materially affect results, including:
- Conflicts in Europe and the Middle East.
- Economic conditions affecting healthcare providers and payers.
- Regulatory approvals, reimbursement decisions, and government actions.
- Product defects, recalls, or quality management failures.
- Supply chain disruptions and cybersecurity threats.
- Foreign exchange volatility and changes in taxation regulations.
Investor Verification Checklist
- Verify the effective date of Deepak Nath's new role at Reckitt Benckiser Group plc (April 1, 2026).
- Confirm whether this appointment impacts Mr. Nath's availability or focus as CEO of Smith & Nephew.
- Review the most recent Form 20-F for detailed financial performance, as this 6-K does not contain financial statements.
- Monitor upcoming regulatory filings for any updates on the company's $6.2 billion 2025 sales performance relative to current market conditions.